Business · NEWS EXPLAINER
Cencora agrees to acquire American Oncology Network in deal worth up to $2.4 billion
The signed agreement combines $2.3 billion at closing with up to $100 million in contingent rights, while shareholder and regulatory approvals are still required.
Cencora signed a definitive agreement to acquire the American Oncology Network interests it does not already own, valuing AON at up to $2.4 billion. The amount comprises $2.3 billion at closing and contingent value rights of up to $100 million.
AON brings more than 350 oncology providers across 21 states. The transaction is not complete: it still needs regulatory clearances, AON shareholder approval and other customary closing conditions.
The headline value has three distinct parts
The announced enterprise value is up to $2.4 billion: $2.3 billion at closing plus contingent value rights worth as much as $100 million if specified conditions are met. Cencora already owns about 4% of AON and agreed to acquire the interests it does not own.
An equity rollover could reduce the cash paid at closing
Some AON shareholders may retain up to 25% through an equity rollover. If the full 25% is retained, Cencora expects to pay about $1.7 billion to raise its ownership to 75%. That is a conditional closing scenario, not a change to the stated $2.4 billion enterprise value.
AON adds a physician-led network across 21 states
AON operates a physician-led network of more than 350 oncology providers across 21 states. Cencora said the combination would extend its management-services footprint into 12 additional states and add capabilities for independent oncology practices. The company also said clinical decisions would remain with AON physicians.
The deal extends a broader community-oncology consolidation trend
Reuters reported that community oncology has attracted several large transactions as distributors and care platforms seek growth outside hospital settings. The report cited Cardinal Health’s $1.12 billion Integrated Oncology Network deal, McKesson’s $2.49 billion Florida Cancer Specialists transaction and Cencora’s $5 billion majority investment in OneOncology as recent comparisons.
Approvals still stand between the agreement and completion
The companies announced a definitive agreement, not a completed acquisition. Closing requires regulatory clearances, AON shareholder approval and other customary conditions. Cencora expects the acquisition to add to adjusted diluted earnings per share in the second year after closing, but that remains a forward-looking company expectation.
